Breaking News, Financial News

Covance 3Q

Late-stage revenues were up 24%, but early-stage revenues were down 9% in 3Q09

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Covance 3Q09 3Q Revenues: $475 million (+8%) 3Q Earnings: $51 million (flat) YTD Revenues: $1.4 billion (+7%) YTD Earnings: $134 million (-11%) Comments: Late-Stage Development accounted for 59% of 3Q revenues and was up 24% to $279 million. Early Development was down 9% to $196 million. For YTD, Late-Stage is up 21% to $794 million and Early is down 7% to $631 million. 3Q09 net income got a $9 million boost from the save of IV/WRSand $2 million from a favorable tax settlement....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters